접합백신 시장 보고서(2026년)

Conjugate vaccines, also referred to as immunogen conjugates, are advanced modulators of the immune system that are widely used to provide protection against invading pathogens or to stimulate the production of specific antibodies against a target molecule. The conjugation process strengthens the immune response and enables more effective recognition of the pathogen by the immune system.

The primary types of conjugate vaccines include monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines contain a single conjugated antigen, usually aimed at a specific pathogen or strain, and are used to prevent infections caused by bacteria with a polysaccharide capsule, such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis. These vaccines are developed against various bacterial and viral pathogens to treat diseases including pneumococcal, influenza, meningococcal, and typhoid infections, for both pediatric and adult patients, and are used in hospitals, clinics, homecare settings, and other healthcare environments.

Tariffs have moderately impacted the conjugate vaccine market by increasing costs associated with imported raw materials, carrier proteins, and specialized manufacturing equipment used in vaccine conjugation. These cost pressures affect bacterial conjugate vaccine segments and multivalent products more significantly, with emerging regions in Asia-Pacific and Africa facing supply delays due to reliance on imports. However, tariffs are also encouraging local manufacturing, technology transfer agreements, and regional self-sufficiency in vaccine production, supporting long-term market resilience.

The conjugate vaccine market research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including conjugate vaccine industry global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $21.26 billion in 2025 to $23.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to government-led immunization initiatives, high prevalence of bacterial infections, support from global health organizations, proven efficacy of conjugate vaccines, increasing pediatric population.

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising demand for combination vaccines, expansion of adult vaccination programs, increased funding for vaccine r&d, growing focus on antimicrobial resistance, improving cold chain infrastructure. Major trends in the forecast period include expansion of pediatric immunization programs, rising adoption of multivalent conjugate vaccines, increasing focus on long-term immunogenicity, growth in public-private vaccine partnerships, advancements in carrier protein technologies.

The increasing incidence of infectious diseases is anticipated to drive the expansion of the conjugate vaccine market. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly between individuals, from animals to humans, or through environmental exposure. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among high-risk groups such as infants and young children. For example, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. During the same period, the incidence rate grew from 2.5 per 100,000 people in 2022 to 2.9 in 2023. Consequently, the growing burden of infectious diseases is contributing to the growth of the conjugate vaccine market.

Key companies operating in the conjugate vaccine market are concentrating on the development of next-generation conjugate vaccines to deliver broader protection against multiple pneumococcal serotypes and reduce disease burden among vulnerable populations. These next-generation conjugate vaccines link bacterial polysaccharides to carrier proteins to enhance immune responses, especially in infants and immunocompromised individuals, providing improved protection, longer-lasting immunity, and greater effectiveness compared with conventional vaccines. For instance, in August 2025, Pfizer Ltd. launched its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India. This launch strengthened the company's conjugate vaccine portfolio by offering expanded protection against pneumococcal disease and supporting improved public health outcomes.

In December 2024, Sanofi expanded its collaboration with SK bioscience to advance the development of next-generation pneumococcal conjugate vaccines (PCV21). Through this partnership, Sanofi aims to accelerate the phase 3 clinical development program for PCV21 and enhance its vaccine portfolio by leveraging SK bioscience's expertise in vaccine research, development, and manufacturing.

Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Conjugate Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The conjugate vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
• 2) By Pathogen: Bacterial; Viral
• 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
• 4) By Patient: Pediatric; Adults
• 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
• Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited; Serum Institute of India Private Limited; Biological E. Limited; Bavarian Nordic A/S; CSL Limited; Novartis AG; GreenSignal Bio Pharma Limited; Taj Pharmaceuticals Limited; Vaxcyte Inc.; Neuron Biotech Co. Ltd.; Bio-Med Pvt. Ltd.; Sinovac Biotech Ltd.; Takeda Pharmaceutical Company Limited; Valneva SE; Dynavax Technologies Corporation; Emergent BioSolutions Inc.; Hualan Biological Engineering Inc.; Panacea Biotec Ltd.; Protein Sciences Corporation; Seqirus
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Conjugate Vaccine Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Conjugate Vaccine Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Conjugate Vaccine Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Conjugate Vaccine Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expansion Of Pediatric Immunization Programs
  • 4.2.2 Rising Adoption Of Multivalent Conjugate Vaccines
  • 4.2.3 Increasing Focus On Long-Term Immunogenicity
  • 4.2.4 Growth In Public-Private Vaccine Partnerships
  • 4.2.5 Advancements In Carrier Protein Technologies

5. Conjugate Vaccine Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Vaccination Centers
• 5.4 Research Institutes
• 5.5 Public Health Agencies

6. Conjugate Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Conjugate Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Conjugate Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Conjugate Vaccine Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Conjugate Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Conjugate Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Conjugate Vaccine Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Conjugate Vaccine Market Segmentation

• 9.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
• 9.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bacterial, Viral
• 9.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pneumococcal, Influenza, Meningococcal, Typhoid
• 9.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric, Adults
• 9.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Homecare Settings, Other End Users

10. Conjugate Vaccine Market Regional And Country Analysis

• 10.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Conjugate Vaccine Market

• 11.1. Asia-Pacific Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Conjugate Vaccine Market

• 12.1. China Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Conjugate Vaccine Market

• 13.1. India Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Conjugate Vaccine Market

• 14.1. Japan Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Conjugate Vaccine Market

• 15.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Conjugate Vaccine Market

• 16.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Conjugate Vaccine Market

• 17.1. South Korea Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Conjugate Vaccine Market

• 18.1. Taiwan Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Conjugate Vaccine Market

• 19.1. South East Asia Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Conjugate Vaccine Market

• 20.1. Western Europe Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Conjugate Vaccine Market

• 21.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Conjugate Vaccine Market

• 22.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Conjugate Vaccine Market

• 23.1. France Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Conjugate Vaccine Market

• 24.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Conjugate Vaccine Market

• 25.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Conjugate Vaccine Market

• 26.1. Eastern Europe Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Conjugate Vaccine Market

• 27.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Conjugate Vaccine Market

• 28.1. North America Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Conjugate Vaccine Market

• 29.1. USA Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Conjugate Vaccine Market

• 30.1. Canada Conjugate Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Conjugate Vaccine Market

• 31.1. South America Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Conjugate Vaccine Market

• 32.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Conjugate Vaccine Market

• 33.1. Middle East Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Conjugate Vaccine Market

• 34.1. Africa Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Segmentation By Pathogen, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Conjugate Vaccine Market Regulatory and Investment Landscape

36. Conjugate Vaccine Market Competitive Landscape And Company Profiles

• 36.1. Conjugate Vaccine Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Conjugate Vaccine Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Conjugate Vaccine Market Company Profiles
  • 36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis

37. Conjugate Vaccine Market Other Major And Innovative Companies

• Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc.

38. Global Conjugate Vaccine Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Conjugate Vaccine Market

40. Conjugate Vaccine Market High Potential Countries, Segments and Strategies

• 40.1 Conjugate Vaccine Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Conjugate Vaccine Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Conjugate Vaccine Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer